Everest Medicines signs equity purchase agreement with Haisen Biopharmaceuticals (Asia) Co., Ltd.

- The two parties have signed an equity purchase agreement to acquire all shares of Haisen Biopharmaceuticals (Singapore) Co., Ltd. Leveraging its established regional commercial platform covering 14 marketed chronic disease products, the acquisition aims to accelerate business expansion in the Asia-Pacific region.

- The total consideration for this transaction amounts to $250 million (approximately RMB 1.722 billion), payable in three installments.

- This transaction is expected to generate near-term revenue and profit contributions for Everest Medicines. Haisen Biopharmaceuticals (Singapore) Co., Ltd. is projected to achieve normalized revenue of $82.23 million (approximately RMB 566 million) and EBITDA of $27.27 million (approximately RMB 188 million) by 2025.

– This transaction will complement Everest Medicines' existing pipeline, unlock synergies, strengthen its chronic disease presence in the Asia-Pacific region, and reinforce its position as the preferred partner for global innovative assets in China and the Asia-Pacific.

Everest Medicines (HKEX 1952.HK, hereinafter referred to as the 'Company'), a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing, and commercialization, today announced that its wholly-owned Singaporean subsidiary, EverSea Medicines (Singapore) Pte. Ltd., has signed a share purchase agreement with Haisen BioPharma (Asia) Limited to acquire all shares of its wholly-owned subsidiary, Haisen BioPharma (Singapore) Pte. Ltd.

This transaction will complement the Company’s existing pipeline, unleash synergies between its product portfolio and commercialization capabilities, further enhance its presence and commercialization abilities in chronic diseases across the Asia-Pacific region, and solidify Everest Medicines’ leading position as the preferred partner for global innovative assets in China and the Asia-Pacific, while expanding its business scale.

According to the agreement:

– The total consideration for this transaction is $250 million (approximately RMB 1.72 billion), which will be paid in three installments, subject to the fulfillment or waiver by the buyer of all relevant conditions precedent for each payment tranche. The first installment amounts to $150 million (approximately RMB 1.03 billion), representing 60% of the total consideration, payable at closing; the second installment is $50 million (approximately RMB 344 million), representing 20% of the total consideration, expected to be due in the first quarter of 2028; the third installment is $50 million (approximately RMB 344 million), also representing 20% of the total consideration, expected to be due in the first quarter of 2029.

– The refundable deposit of RMB 200 million paid under the terms of the letter of intent signed in March 2026 will be fully refunded by Haisen BioPharma (Asia) Limited within 10 business days after the completion of the closing.

– Upon completion of the closing, Haisen BioPharma (Singapore) Pte. Ltd. will become an indirect wholly-owned subsidiary of Everest Medicines, and its financial results will be consolidated into the Company’s financial statements.

Through this acquisition, Everest Medicines will extend its proven commercialization capabilities and innovative drug portfolio from the China market to the broader Asia-Pacific region, enhancing regional presence, accelerating market access and commercialization of both current and future products, and laying the groundwork for the international expansion of subsequent innovative products.

Haisen BioPharma (Singapore) Pte. Ltd. holds commercial rights to 14 branded chronic disease products across multiple countries and regions in the Asia-Pacific, having established a pan-Asia-Pacific commercial platform supported by a professional sales team of approximately 120 members, serving a large and continuously growing chronic disease patient population. For the fiscal year ending December 31, 2025, Haisen BioPharma (Singapore) Pte. Ltd. achieved normalized revenue of $82.23 million (approximately RMB 566 million), with EBITDA (earnings before interest, taxes, depreciation, and amortization) of $27.27 million (approximately RMB 188 million).

Currently, the core Asia-Pacific markets have a combined population exceeding 2 billion, with a large and growing patient population. The unmet medical needs in chronic disease management are significant, offering substantial market potential.

Everest Medicines focuses on the treatment of chronic diseases in areas such as cardiovascular, renal, and metabolic (CKM) therapies, and has established a leading innovative drug commercialization platform for chronic diseases in China. The company’s core commercialized products, including Nefukang®, Weishiping®, and Yijia®, have not only been launched in mainland China but have also successively received New Drug Application (NDA) approvals in other relevant regions of Asia and have been included in local reimbursement systems. As part of its long-term strategy, the company continues to evaluate the acquisition of pharmaceutical enterprises in the Asia-Pacific region that possess a mature market position, clear growth prospects, and stable, sustainable returns, further strengthening its regional presence and expanding its business scale. This transaction will accelerate the commercialization process of the company's existing products in the Asian market, drive overseas revenue growth, and further expand its footprint in the Asia-Pacific region while reinforcing its global strategic layout.

In the coming years, China's innovative drugs entering the Asia-Pacific market will encounter significant development opportunities. With comprehensive advantages in clinical value, affordability, and accessibility, Chinese innovative drugs continue to align with the growing healthcare needs of the Asia-Pacific region. Meanwhile, the regulatory pathways and market access frameworks in this region are continuously improving, and awareness of innovative therapies is increasing, leading to greater acceptance of Chinese innovative drugs. In this context, the key to long-term success lies not only in the products themselves but also in establishing localized operational capabilities in critical areas such as registration, market access, medical affairs, and commercialization, thereby building sustained competitive advantages in this rapidly growing market.

Everest Medicines is committed to becoming a leading global integrated biopharmaceutical company in Asia. This transaction will enable the company to seize growth opportunities in the Asia-Pacific market and provide crucial support for the international expansion of future innovative products.

Information on the conference call and webcast

The company will hold a Chinese-language online investor meeting at 8:30 AM Beijing Time on April 8, 2026 (8:30 PM Eastern Time on April 7), during which it will communicate regarding the proposed acquisition of Haisen Bio's Asia-Pacific business.

Participants can join the Chinese meeting via the following link:

Webcast Link: https://research.citics.com/tel/info/1_2081006

Participants can also dial into the conference call using the following dial-in information:

Mainland China 4008108228/4008108128

Overseas +861058084166

Hong Kong, China +85230051313/+85230051355

Taiwan, China 0800666425

Singapore +6568185374

United States +16462543594

United Kingdom +441213680466

Meeting password: 046559

Participants can also listen to simultaneous interpretation (English) via the following link:

https://clsa.zoom.us/webinar/register/WN_zjwC8HzwS_-NBYMbuuyjoA#/registration

(Select English as the language; Zoom meeting ID: 852 4080 9179)

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing, and commercialization, committed to addressing unmet medical needs in global markets. The management team of Everest Medicines possesses deep expertise and extensive experience from leading pharmaceutical enterprises in China and globally. The company owns a commercial-scale global production base in Jiashan, Zhejiang, constructed strictly in accordance with the GMP requirements of the National Medical Products Administration (NMPA) and the European Medicines Agency (EMA), as well as the WHO PQ standards.

The company focuses on the treatment of diseases in areas such as autoimmune disorders, ophthalmology, acute and critical care, and CKM (cardiovascular, kidney, and metabolic diseases). It has built a commercial platform integrating an omnichannel commercialization system with full lifecycle commercial capabilities for pharmaceuticals. Based on its self-developed mRNA platform with global rights, the company continues to advance its existing pipelines, including mRNA in vivo CAR-T and mRNA cancer vaccines. At the same time, by acquiring and incubating promising platforms, it expands R&D capabilities while strengthening its global footprint and accelerating international development. For more information, visit the company’s official website: www.everestmedicines.com

About Haisen Biopharmaceuticals (Asia) Co., Ltd. and Haisen Biopharmaceuticals (Singapore) Co., Ltd.

Haisen Biopharmaceuticals (Asia) Limited is a company incorporated in the Cayman Islands, mainly engaged in investment holding.

Haisen Biopharmaceuticals (Singapore) Limited is a company incorporated in Singapore, primarily focused on the commercialization of prescription drugs in chronic diseases and critical care areas, particularly within cardiovascular and metabolic segments. The company holds asset rights to 14 branded products in the chronic disease space across multiple countries in the Asia-Pacific region, including Marketing Authorization Holder (MAH) rights, trademarks, and extensive commercialization rights.

Forward-Looking Statements

This press release may contain certain forward-looking statements based on the Company's or management’s current views, beliefs, and expectations regarding the Company's business operations and financial condition at the time the statements were made. Such statements may be expressed using terms such as 'will,' 'expect,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'confident,' and similar expressions. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the Company’s control and difficult to predict. Therefore, actual results may differ materially from the information contained in these forward-looking statements due to various factors and assumptions, including changes and developments in our business, competitive environment, political, economic, legal, and social conditions. Neither the Company nor its subsidiaries, directors, officers, advisors, or agents have any obligation to update the forward-looking statements contained in this press release to reflect subsequent information, future events, or circumstances, unless required by law.

39K Views